Regeneron's antibody cocktail improves COVID-19 patients

By The Science Advisory Board staff writers

September 30, 2020 -- An investigational antibody cocktail by Regeneron Pharmaceuticals reduced the viral loads and improved the systems of nonhospitalized COVID-19 patients, according to data from its phase I/II/III trial.

REGN-COV2, a combination of two monoclonal antibodies, also had a positive effect in reducing medical visits, according to the ongoing, randomized double-blind trial that aims to measure the benefit of adding REGN-COV2 to the usual standard of care. Of the first 275 patients enrolled, approximately 45% were seropositive and 41% were seronegative. REGN-COV2 reduced viral load through day seven in seronegative patients.

The trial is included in a larger research program that is studying the cocktail for treating hospitalized patients and for preventing infections in those who have been exposed to COVID-19 patients.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here